论文部分内容阅读
目的探讨依达拉奉对心肌梗死溶栓治疗后再灌注损伤的影响。方法选取2014年7月—2015年4月黄石市中心医院普爱院区心血管内科收治的心肌梗死患者300例,采用随机数字表法分为对照组和观察组,每组150例。在常规治疗基础上,对照组患者给予尿激酶治疗,治疗组患者在对照组基础上给予依达拉奉治疗。比较两组患者再灌注心律失常发生率及心功能指标。结果观察组患者再灌注心律失常发生率低于对照组(P<0.05)。观察组患者左心室收缩末期容积指数、左心室舒张末期容积指数、室壁运动积分指数均低于对照组,左心室射血分数高于对照组(P<0.05)。结论依达拉奉可减少心肌梗死溶栓治疗后再灌注损伤的发生,有助于改善患者心功能。
Objective To investigate the effect of edaravone on reperfusion injury after myocardial thrombolysis in patients with myocardial infarction. Methods From July 2014 to April 2015, 300 patients with myocardial infarction were admitted to Department of Cardiology, Puai Hospital of Huangshi Central Hospital. The patients were divided into control group and observation group with 150 cases in each group. On the basis of routine treatment, patients in the control group were treated with urokinase, and patients in the treatment group were treated with edaravone on the basis of the control group. The incidence of reperfusion arrhythmia and cardiac function were compared between the two groups. Results The incidence of reperfusion arrhythmia in observation group was lower than that in control group (P <0.05). Left ventricular end-systolic volume index, left ventricular end-diastolic volume index and ventricular wall motion integral index in observation group were lower than those in control group, and left ventricular ejection fraction was higher than that in control group (P <0.05). Conclusion Edaravone can reduce the incidence of reperfusion injury after thrombolytic therapy of myocardial infarction and improve cardiac function.